(19)

(11)

EP 4 136 090 A1

(12)

(43) Date of publication: 22.02.2023 Bulletin 2023/08 (21) Application number: 21722702.4 (22) Date of filing: 09.04.2021

(51) International Patent Classification (IPC):  C07D 519/00(2006.01) A61P 35/00(2006.01) A61K 31/497(2006.01) (52) Cooperative Patent Classification (CPC): C07D 519/00; A61P 35/00 (86) International application number: PCT/US2021/026611 (87) International publication number: WO 2021/211380 (21.10.2021 Gazette 2021/42)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 17.04.2020 US 202063011701 P 19.02.2021 US 202163151354 P (71) Applicant: Loxo Oncology, Inc. Indiana 46285 (US)

(72) Inventors: BHARDWAJ, Rajni Miglani Indianapolis, Indiana 46206-6288 (US) KERR, Mark Steven Indianapolis, Indiana 46206-6288 (US) KJELL, Douglas Patton Indianapolis, Indiana 46206-6288 (US) MERRITT, Jeremy Miles Indianapolis, Indiana 46206-6288 (US) SELBO, Jon Gordon Indianapolis, Indiana 46206-6288 (US) VISWANATH, Shekhar Krishna Indianapolis, Indiana 46206-6288 (US) (74) Representative: Smith, Andrew George  Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU Bracknell, Berkshire RG12 1PU (GB)